Summary
Somatostatin receptors (SR) have been identified in vitro in normal brain tissue, in neuro-endocrine tumours and in cerebral gliomas WHO grade 1 or 2 by autoradiography or using somatostatin-gold conjugates. In vivo, SR detection has become possible by scintigraphy applying the somatostatin analogue octreotide, radio-labelled with111Indium. It was supposed that expression of SR in cerebral gliomas corresponds to low grade tumour malignancy and that, in vivo, somatostatin receptor scintigraphy (SRS) could refine and improve the WHO grading system for cerebral gliomas.
Nineteen patients with cerebral gliomas (grade 2: n=8, grade 3: n=3, grade4: n=8) were examined with111In (DTPA-octreotide) to evaluate, whether SRS could improve the pre-operative estimation of tumour biology and the postoperative management. The results of SRS were related with the histological findings and with the in vitro demonstration of somatostatin-binding sites on cultured tumour cells incubated with a somatostatin-gold conjugate.
In vivo, none of the patients with glioma grade 2 showed enhanced tracer uptake in the SRS, whereas in vitro SR were detected in cultured tumour tissue in 5 out of 5 cases. Every patient with glioma grade 3 or 4 demonstrated a high focal uptake of111In (DTPA-octreotide), as shown by SRS. Three patients with glioma grade 4, additionally examined with 99mTc-DTPA, showed an increased tracer uptake within the tumour area when compared with results of SRS. In vitro, SR were detected on tumour cell surface in 5 out of 6 tissue samples from patients with gliomas grade 3 or 4. One patient harbouring a cerebral abscess presented with a high focal tracer uptake in the SRS but with absence of somatostatinbinding sites in vitro.
We concluded, that in glioma patients enhanced tracer uptake in receptor scintigraphy with111In (DTPA-octreotide) does not depend on the presence of SR in tumour tissue but on the dysfunction of the blood-brain barrier. Thus, SRS does not improve the preoperative glioma grading or postoperative management in patients with cerebral tumours of glial origin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991) [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor positive tumours: synthesis, radiolabeling and in vitro validation. Life Sci 49: 1583–1591
Krisch B, Buchholz C, Mentlein R (1991) Somatostatin binding sites on rat diencephalic astrocytes. Light-microscopic study in vitro and in vivo. Cell Tissue Res 263: 253–263
Krisch B, Buchholz C, Mentlein R, Turzinsky A (1993) Visualisation of neuropeptide binding sites on individual telencephalic neurons. Cell Tissue Res (in press)
Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocrine Rev 12: 450–482
Lamberts SWJ, Koper J, Reubi JC, Krenning EP (1992) Endocrine aspects of diagnosis and treatment of primary brain tumours. Clin Endocrinol 37: 1–10
Mentlein R, Buchholz C, Krisch B (1989) Binding and internalization of gold-conjugated somatostatin growth hormone-releasing hormone in cultured rat somatotropes. Cell Tissue Res 258: 309–317
Mentlein R, Buchholz C, Krisch B (1990) Somatostatin binding sites on rat telencephalic astrocytes. Light- and electron-microscopy study in vitro and in vivo. Cell Tissue Res 262: 431–443
Reichlin S (1983) Somatostatin. N Engl J Med 309: 1495–1563
Reubi JC, Cortes R, Maurer R, Probst A, Palacios JM (1986) Distribution of somatostatin receptors in the human brain: an autoradiographic study. Neuroscience 18: 329–346
Reubi JC, Kvols L, Krenning EP, Lamberts SWJ (1990) Distribution of somatostatin receptors in normal and tumour tissues. Metabolism 39: 78–81
Reubi JC, Laissue J, Krenning EP, Lamberts SWJ (1992) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Molec Biol 43: 27–35
Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N, Schicha H (1993) Somatostatin receptor scintigraphy in brain tumours. Horm Metabol Res Series [Suppl] 27: 59–62
Torp SH, Helseth E, Dalen A, Unsgaard G (1992) Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 117: 182–186
Author information
Authors and Affiliations
Additional information
The article is dedicated to Prof. H. Leonhardt on the occasion of his 75th birthday.
Rights and permissions
About this article
Cite this article
Luyken, C., Hildebrandt, G., Scheidhauer, K. et al. 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta neurochir 127, 60–64 (1994). https://doi.org/10.1007/BF01808548
Issue Date:
DOI: https://doi.org/10.1007/BF01808548